AR012856A1 - Utilizacion de un compuesto derivado de la 1,2,3,6-tetrahidropiridina o de una de sus sales y solvatos farmaceuticamente aceptables, y un compuestoderivado de la 1,2,3,6-tetrahidropiridina y sus sales y solvatos farmaceuticamente aceptables. - Google Patents
Utilizacion de un compuesto derivado de la 1,2,3,6-tetrahidropiridina o de una de sus sales y solvatos farmaceuticamente aceptables, y un compuestoderivado de la 1,2,3,6-tetrahidropiridina y sus sales y solvatos farmaceuticamente aceptables.Info
- Publication number
- AR012856A1 AR012856A1 ARP980102423A ARP980102423A AR012856A1 AR 012856 A1 AR012856 A1 AR 012856A1 AR P980102423 A ARP980102423 A AR P980102423A AR P980102423 A ARP980102423 A AR P980102423A AR 012856 A1 AR012856 A1 AR 012856A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- halogen
- tetrahydropyridine
- solvates
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Utilizacion de un compuesto derivado de 1,2,3,6-tetrahidropiridina o de una de sus sales y solvatos farmacéuticamente aceptables de formula I en la cualR1 representa un halogeno o un grupo CF3 C1-4 alcoxi; Y representa un átomo de nitrogeno o un grupo CH; Z y Z representan cada uno, el hidrogeno o ungrupo C1-3 alquilo, o bien uno representa hidrogeno y el otro un grupo hidroxi, o también los dos juntos, representa un grupo oxo; Z representa: un radicalfenilo; un radical fenilo monosubstituidopor un substituyente X siendo X, a) un grupo C1-6 alquilo, C1-6 alcoxi, C3-7 carboxialquilo, C1-4 alcoxicarbonilC1-6 alquilo, C3-7 carboxialcoxi o C1-4 alcoxicarbonil C1-6 alcoxi; b)un grupo elegido entre un C3-7 cicloalquilo, C3-7 cicloalquiloxi,C3-7 ilciclaalquilmetilo, C3-7 cicloalquilamino, y ciclohexenilo, pudiendo dicho grupo ser substituido por un halogeno, hidroxi C1-4 alcoxi, carboxi C1-4alcoxicarbonilo, amino, mono-, o di- C1-4 alquilamino; c)un grupo elegido entre fenilo, fenoxi,fenilamino, N-C1-3 alquilfenilamino, fenilmetilo, feniletilo,fenilcarbonilo, feniltio, fenilsulfonilo, fenilsulfinilo o estirilo, pudiendo dicho grupo ser mono o polisubstituido en el grupo fenilo por un halogeno, CF3C1-6 alquilo, C1-4 alcoxi, ciano, amino, mono- o di-C1-6, C1-4 alquilamino, C1-4 acilamino, carboxi, C1-4 alcoxicarbonilo, aminocarbonilo, mono- o di-C1-4alquilaminocarbonilo,amino C1-4 alquilo, hidroxi C1-6 alquilo o halogeno C1-4 alquilo; un radical fenilo disubstituido por un substituyente R2, siendo R2 unhalogeno o un grupo hidroxi, metilo, etilo, C3-6 alquilo, C1-4 alcoxi o trifluorometilo y por substituyente X, siendo X tal como se ha definidoanteriormente; un radical 1-naftilo o 2-naftilo; un radical 1-naftilo o 2-naftilo, substituido en las posiciones 5,6,7 y/u 8 por uno o dos grupos
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9706522A FR2763847B1 (fr) | 1997-05-28 | 1997-05-28 | Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR012856A1 true AR012856A1 (es) | 2000-11-22 |
Family
ID=9507317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102423A AR012856A1 (es) | 1997-05-28 | 1998-05-26 | Utilizacion de un compuesto derivado de la 1,2,3,6-tetrahidropiridina o de una de sus sales y solvatos farmaceuticamente aceptables, y un compuestoderivado de la 1,2,3,6-tetrahidropiridina y sus sales y solvatos farmaceuticamente aceptables. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US6342505B1 (es) |
| EP (1) | EP1017385B1 (es) |
| JP (1) | JP2002511855A (es) |
| AR (1) | AR012856A1 (es) |
| AT (1) | ATE245027T1 (es) |
| AU (1) | AU7774898A (es) |
| BR (1) | BR9809444A (es) |
| CA (1) | CA2290557C (es) |
| DE (1) | DE69816456T2 (es) |
| DK (1) | DK1017385T3 (es) |
| ES (1) | ES2201502T3 (es) |
| FR (1) | FR2763847B1 (es) |
| NO (1) | NO324074B1 (es) |
| PT (1) | PT1017385E (es) |
| WO (1) | WO1998053821A1 (es) |
| ZA (1) | ZA984564B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757510B1 (fr) * | 1996-12-23 | 2000-01-07 | Sanofi Sa | Forme microparticulaire d'un derive de tetrahydropyridine |
| FR2763847B1 (fr) * | 1997-05-28 | 2003-06-06 | Sanofi Sa | Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1 |
| FR2831166B1 (fr) * | 2001-10-18 | 2004-02-27 | Sanofi Synthelabo | Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant |
| GB0226930D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| US20090076048A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched xaliproden |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2531707A1 (fr) | 1982-08-16 | 1984-02-17 | Midy Spa | Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques |
| FR2662355B1 (fr) | 1990-05-22 | 1994-11-10 | Sanofi Sa | Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux. |
| FR2662442A1 (fr) | 1990-05-23 | 1991-11-29 | Midy Spa | Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant. |
| US5618822A (en) | 1990-05-23 | 1997-04-08 | Sanofi | N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them |
| FR2672213B1 (fr) * | 1991-02-05 | 1995-03-10 | Sanofi Sa | Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres. |
| HU211019B (en) | 1991-12-02 | 1995-09-28 | Richter Gedeon Vegyeszet | Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds |
| US5522011A (en) | 1993-09-27 | 1996-05-28 | International Business Machines Corporation | Speech coding apparatus and method using classification rules |
| WO1996021449A1 (en) | 1995-01-11 | 1996-07-18 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical composition of indene derivatives for regulating apoptosis |
| FR2736053B1 (fr) * | 1995-06-28 | 1997-09-19 | Sanofi Sa | Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines |
| FR2757160B1 (fr) * | 1996-12-13 | 1999-03-12 | Sanofi Sa | 1-phenylalkyl-1,2,3,6-tetrahydropyridines |
| FR2757161B1 (fr) * | 1996-12-13 | 1999-03-12 | Sanofi Sa | Diphenylalkyl-tetrahydropyridines |
| FR2762514B1 (fr) * | 1997-04-29 | 1999-10-22 | Sanofi Sa | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation |
| FR2763847B1 (fr) * | 1997-05-28 | 2003-06-06 | Sanofi Sa | Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1 |
-
1997
- 1997-05-28 FR FR9706522A patent/FR2763847B1/fr not_active Expired - Fee Related
-
1998
- 1998-05-20 EP EP98925747A patent/EP1017385B1/fr not_active Expired - Lifetime
- 1998-05-20 US US09/423,884 patent/US6342505B1/en not_active Expired - Fee Related
- 1998-05-20 ES ES98925747T patent/ES2201502T3/es not_active Expired - Lifetime
- 1998-05-20 WO PCT/FR1998/001000 patent/WO1998053821A1/fr active IP Right Grant
- 1998-05-20 DK DK98925747T patent/DK1017385T3/da active
- 1998-05-20 AU AU77748/98A patent/AU7774898A/en not_active Abandoned
- 1998-05-20 CA CA002290557A patent/CA2290557C/en not_active Expired - Fee Related
- 1998-05-20 JP JP50030999A patent/JP2002511855A/ja not_active Withdrawn
- 1998-05-20 AT AT98925747T patent/ATE245027T1/de not_active IP Right Cessation
- 1998-05-20 DE DE69816456T patent/DE69816456T2/de not_active Expired - Fee Related
- 1998-05-20 BR BR9809444-0A patent/BR9809444A/pt not_active Application Discontinuation
- 1998-05-20 PT PT98925747T patent/PT1017385E/pt unknown
- 1998-05-26 AR ARP980102423A patent/AR012856A1/es unknown
- 1998-05-28 ZA ZA984564A patent/ZA984564B/xx unknown
-
1999
- 1999-11-26 NO NO19995821A patent/NO324074B1/no unknown
-
2001
- 2001-11-20 US US10/044,223 patent/US6693118B2/en not_active Expired - Fee Related
-
2004
- 2004-02-05 US US10/773,073 patent/US7320982B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE245027T1 (de) | 2003-08-15 |
| DK1017385T3 (da) | 2003-10-27 |
| NO995821L (no) | 2000-01-28 |
| US6693118B2 (en) | 2004-02-17 |
| DE69816456D1 (de) | 2003-08-21 |
| FR2763847B1 (fr) | 2003-06-06 |
| US20040157868A1 (en) | 2004-08-12 |
| NO324074B1 (no) | 2007-08-06 |
| US7320982B2 (en) | 2008-01-22 |
| AU7774898A (en) | 1998-12-30 |
| BR9809444A (pt) | 2000-06-13 |
| CA2290557A1 (en) | 1998-12-03 |
| DE69816456T2 (de) | 2004-04-15 |
| US6342505B1 (en) | 2002-01-29 |
| EP1017385A1 (fr) | 2000-07-12 |
| JP2002511855A (ja) | 2002-04-16 |
| CA2290557C (en) | 2007-11-27 |
| EP1017385B1 (fr) | 2003-07-16 |
| US20020091143A1 (en) | 2002-07-11 |
| NO995821D0 (no) | 1999-11-26 |
| ES2201502T3 (es) | 2004-03-16 |
| PT1017385E (pt) | 2003-10-31 |
| ZA984564B (en) | 1998-12-03 |
| WO1998053821A1 (fr) | 1998-12-03 |
| FR2763847A1 (fr) | 1998-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS52978B (en) | FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS | |
| AR017700A1 (es) | Un compuesto derivado de imidazol, un procedimiento para prepararlo, compuestos utiles como intermediarios para prepararlo, y una composicionfarmaceutica que comprende a dicho compuesto derivado de imidazol | |
| CO5150227A1 (es) | Compuestos de triazol y su utilizacion | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| NO20034644D0 (no) | Fettsyrer med halvlange kjeder, glycerider og analoger som neutrofile overlevelses- og aktiveringsfaktorer | |
| EA200700519A1 (ru) | Производные n-2-адамантанил-2-феноксиацетамида в качестве ингибиторов 11-бета гидроксистероид-дегидрогеназы | |
| AR012856A1 (es) | Utilizacion de un compuesto derivado de la 1,2,3,6-tetrahidropiridina o de una de sus sales y solvatos farmaceuticamente aceptables, y un compuestoderivado de la 1,2,3,6-tetrahidropiridina y sus sales y solvatos farmaceuticamente aceptables. | |
| ES2190396T3 (es) | Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| AR025976A1 (es) | Inhibidores de fab i. | |
| AR049543A1 (es) | Derivados de la 1-amino-ftalazina, su preparacion y su aplicacion en terapeutica | |
| IL115572A0 (en) | Novel substituted 4-(azanaphthoylamino)-piperidines salts of these and pharmaceutical compositions containing them | |
| BR0317696A (pt) | Composição para branqueamento | |
| BR9810234A (pt) | Utilização de derivados da tetraidropiridna para a preparação de medicamentos para o tratamento das doenças que provocam uma desmielinização | |
| ATE157661T1 (de) | Di(meth)acrylate mit cyclischen carbonatgruppen | |
| AR117951A1 (es) | Derivados de triazolquinoxalina adicionalmente sustituidos | |
| AR036187A1 (es) | Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario | |
| ES2142773B1 (es) | Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida. | |
| PT984691E (pt) | Combinacoes fungicidas compreendendo uma 4-fenoxiquinolina | |
| AR012443A1 (es) | Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos | |
| AR027335A1 (es) | Compuestos de piperidina-4-sulfonamida, proceso de preparacion de los mismos, y composiciones farmaceuticas que los contienen | |
| AR017904A1 (es) | Mezclas fungicidas y procedimentos para controlar hongos nocivos que las emplean. | |
| ES2177275T3 (es) | Derivados de oxadiazolina y su uso como insecticidas. | |
| CO5221057A1 (es) | Componentes y composiciones plagicidas | |
| BG94200A (bg) | Хербицидно средство и метод за борба с плевели | |
| AR038988A1 (es) | Compuestos derivados de quinazolina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen |